BioSpace News Archive

Transit Scientific announced continued success with its XO Score Sheath Platform to treat highly-stenosed cardiovascular lesions using low pressure peripheral transluminal angioplasty (PTA).

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company’s business and pipeline.

IMV Inc. today announced that it is hosting a Research and Development Day” via webcast on Thursday, February 24, 2022 at 8:00am Eastern Time to highlight the differentiating features of its patented DPX delivery platform.

As per the research report by the Transparency Market Research, the global smart healthcare products market is expected to grow at a significant rate of 8.8 % during the forecast period of 2019 to 2027.

Airway homeostasis is a crucial procedure controlled by nose. The infection or inflammation of sinuses resulting in the weakness of nasal lateral wall has significant effect on quality of patient’s life.

Fact.MR – A Market research and competitive intelligence provider: The global sales of animal vaccines are forecast to garner a market valuation of US$ 12 Bn in 2022 and is expected to register a positive market size at a CAGR of 9.2% by accumulating a market valuation of US$ 29 Bn through the assessment period 2022-2032

Immunovia AB announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray™ PanCan-d has been published in Clinical and Translational Gastroenterology.

On Thursday February 24, at 09.00 CET, Devyser Diagnostics AB will host a conference call and an online presentation of its Q4 2021 interim report.

Modra Pharmaceuticals announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with metastatic Castration-Resistant Prostate Cancer compared to the standard-of-care, the IV chemotherapy docetaxel.

MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound a $1.7 million research project for the development of NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.